Friday 6 November 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.

Revenue: +205.6%
EPS: +16.1%
Free cash flow: −65.9%

Quarter to September 2026, against a year earlier

86.43 3.42 +4.12%

Follow DNTH

Alert me

Market cap: $4.6B
P/E: 0.0×
Fwd P/E: −21.5×
Dividend yield: —
F-score: 2/9
Altman Z: 24.31
Beneish M: −4.75
Dividend safety: n/a

Overview

Dianthus Therapeutics, Inc. (DNTH) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Dianthus Therapeutics, Inc. (DNTH) trades at a P/S ratio of 1,823×. Over the past ten years it has ranged from 0.0× (June 2023) to 3,443× (April 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/DNTH/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Dianthus Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/DNTH/metrics/ps-ratio">Dianthus Therapeutics, Inc. (DNTH) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	782×	571.07%
FY2024	116×	457.89%
FY2023	20.9×	—
FY2022	0.0×	—

Period	P/S ratio	Change
Sep 2026	1,858×	(35.24%)
Jun 2026	2,869×	(4.93%)
Mar 2026	3,017×	286.00%
Dec 2025	782×	61.77%
13 more quarters	Free account

Against its own ten years

Low 0.0× High 3,443×

Ten-year median 0.0×

Current reading's percentile 85

Company	P/S ratio
EWTX Edgewise Therapeutics, Inc. compare	n/m
DFTX Definium Therapeutics, Inc. compare	n/m
ERAS Erasca, Inc. compare	n/m
MANE Veradermics Incorporated compare	n/m
LEGN Legend Biotech Corporation Sponsored ADR compare	3.4×
TVTX Travere Therapeutics, Inc. compare	7.2×
CRSP CRISPR Therapeutics AG compare	192×
COGT Cogent Biosciences, Inc. compare	233×
DNTH Dianthus Therapeutics, Inc.	1,823×
Biotechnology industry median	9.4×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Dianthus Therapeutics, Inc. (DNTH) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on DNTH

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on DNTH

Stockrow Weekly